Latest Conference Articles

February 16th 2023, 11:07pm

Genitourinary Cancers Symposium (ASCO GU)

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

February 16th 2023, 10:59pm

Genitourinary Cancers Symposium (ASCO GU)

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.

February 16th 2023, 10:55pm

Transplantation and Cellular Therapy Meetings

Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.

February 16th 2023, 10:35pm

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.

February 16th 2023, 10:33pm

Genitourinary Cancers Symposium (ASCO GU)

Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.

February 16th 2023, 10:05pm

Transplantation and Cellular Therapy Meetings

Surbhi Sidana, MD, discusses the feasibility of administering idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma with renal impairment.

February 16th 2023, 9:55pm

Transplantation and Cellular Therapy Meetings

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

February 16th 2023, 9:32pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

February 16th 2023, 9:10pm

Transplantation and Cellular Therapy Meetings

Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.

February 16th 2023, 8:35pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with darolutamide decreased the likelihood of developing metastatic disease or discontinuing treatment because of adverse effects vs treatment with apalutamide or enzalutamide in patients with non-metastatic castration-resistant prostate cancer.

February 16th 2023, 7:33pm

The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.

February 16th 2023, 7:25pm

Transplantation and Cellular Therapy Meetings

Haploidentical donors and posttransplant cyclophosphamide is a comparable alternative to matched unrelated donors for patients with myelofibrosis receiving blood or marrow transplant without matched sibling donors, although matched sibling donors, when available, remain the preferred donor option.

February 16th 2023, 7:20pm

Transplantation and Cellular Therapy Meetings

The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.

February 16th 2023, 5:55pm

Transplantation and Cellular Therapy Meetings

ADI-001, a first-in-class, allogeneic gamma delta1 CAR T-cell therapy, elicited responses and demonstrated a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

February 16th 2023, 5:42pm

Transplantation and Cellular Therapy Meetings

The dual CD19- and CD20-directed, freshly administered CAR T-cell therapy zamtocabtagene autoleucel elicited a high response rate with deepening responses over time in patients with relapsed/refractory diffuse large B-cell lymphoma.

February 13th 2023, 3:00pm

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas

A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.

February 13th 2023, 2:30pm

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas

Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.

February 7th 2023, 9:23pm

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.

February 7th 2023, 7:30pm

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas

Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.

February 7th 2023, 6:30pm

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.